Abstract 2107P
Background
Thromboembolic events occur in up to 20% of cancer patients during their course of disease. Cancer associated thrombosis (CAT) is a “signum malum” for cancer itself contributing to morbidity and mortality. Optimal measures to prevent CAT are crucial.
Methods
A post hoc analysis of GMaT & ACT4CAT prospective observational phase IV studies conducted in Greece by Hellenic Society for Medical Oncology (HeSMO), aiming to evaluate efficacy & safety of primary CAT prophylaxis with prophylactic (ProD) or intermediate (InterD; 50%-75% of full treatment dose) doses of Low Molecular Weight Heparins (LMWHs) in ambulatory active cancer patients. Both studies conducted according to Helsinki declaration.
Results
1157 patients from 26 oncology centers were recruited. Age: 64.9±12.3 years, BMI: 26.1±45.1 Kg/m2, 59.9% males. Metastasis in 74.5%, Highly Thrombogenic Agents (HTAs) received 82.3%. Anticoagulation agents were (%): 91.2 tinzaparin, 4.6 fondaparinux, 2.3 bemiparin, 1.2 enoxaparin, 0.8 rivaroxaban or apixaban, for 5.1±3.3 months duration. 62% of patients received InterD (1st, 2nd, 3rd,adjuvant & neoadjuvant: 62.4%, 67.3%, 69.8%, 44.1% &71.4% respectively, p=0.004). InterD preferred in men, in those with metastasis, HTAs treatment and receiving erythropoietin agents (ESA) while ProD in those with history of bleeding, heart or vascular, lung or metabolic disease, immobility, surgery, or radiotherapy. Detailed info in the table. Table: 2107P
InterD (N=701) (N/%) | ProD (N=430) (N/%) | p | OR (95%CI) | |
Males | 416/63.7 | 214/55.4 | 0.008 | 1.4 (1.1-1.8) |
Metastasis | 535/79.0 | 259/67.3 | <.0001 | 1.8 (1.4-2.4) |
HTAs | 597/85.4 | 338/79.2 | 0.007 | 1.5 (1.1-2.1) |
ESA | 133/19.0 | 61/14.2 | 0.038 | 1.4 (1.0-2.0) |
Radiotherapy | 126/18.18 | 106/24.9 | 0.007 | 0.7 (0.5-0.9) |
History of | ||||
Bleeding | 2/0.3 | 6/1.4 | 0.031 | 0.2 (0.0-1.0) |
Heart or vascular disease | 139/28 | 80/35.4 | 0.044 | 0.7 (0.5-0.9) |
Immobility | 43/6.1 | 46/10.7 | 0.006 | 0.6 (0.4-0.8) |
Lung disease | 20/4.0 | 17/7.5 | 0.048 | 0.5 (0.3-0.9) |
Metabolic disease | 96/19.3 | 60/26.6 | 0.028 | 0.7 (0.5-0.9) |
Surgery | 269/38.4 | 250/58.3 | <.0001 | 0.5 (0.4-0.6) |
Bleedings | 11/1.6 | 11/2.6 | 0.242 | 0.6 (0.3-1.4) |
Thrombotic events | 11/1.6 | 20/4.7 | 0.002 | 0.3 (0.2-0.7) |
32 patients (2.8%) had thrombotic events (20 in ProD, 11 in InterD, 1 dose unspecified) with higher risk in ProD (OR: 3.1, 95%CI:1.5-6.5, p=0.0021). 26 minor bleeding events reported (2.3%, no dose related difference, p=0.2424).
Conclusions
Common clinical oncology practice was to administer prophylaxis using in most cases LMWHs and frequently in InterD. Selection of anticoagulation dose was based on demographics, cancer characteristics, treatment type and patient medical history. InterD was found to be more efficacious and without safety concerns.
Clinical trial identification
GMaT: NCT03292107; ACT4CAT: NCT03909399.
Editorial acknowledgement
Dr. Abraham Pouliakis Senior Researcher, 2nd Department of Pathology, National and Kapodistrian University of Athens “ATTIKON”, University Hospital, Athens, Greece.
Legal entity responsible for the study
Hellenic Society of Medical Oncology (HeSMO), Athens, Greece.
Funding
Hellenic Society of Medical Oncology (HeSMO), Athens, Greece.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06